In a recent update, BTIG analyst Ryan Zimmerman adjusted the price target for Stryker (SYK, Financial), reducing it from $416 to $403, while maintaining a Buy rating on the stock. This revision is part of a broader analysis anticipating the first-quarter results within the MedTech sector.
Zimmerman underscores that while the MedTech industry has traditionally been viewed as a refuge in volatile times, the emphasis is shifting towards a company’s strategic capabilities in overcoming future challenges. The analyst points out that ongoing complications, such as the persistent trade tensions primarily with China and financial cutbacks at numerous federal healthcare institutions, could prompt concerns among investors. These uncertainties might hinder companies from providing satisfactory assurances, potentially dampening market sentiment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 27 analysts, the average target price for Stryker Corp (SYK, Financial) is $427.38 with a high estimate of $465.00 and a low estimate of $390.00. The average target implies an upside of 22.01% from the current price of $350.28. More detailed estimate data can be found on the Stryker Corp (SYK) Forecast page.
Based on the consensus recommendation from 33 brokerage firms, Stryker Corp's (SYK, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Stryker Corp (SYK, Financial) in one year is $381.38, suggesting a upside of 8.88% from the current price of $350.28. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Stryker Corp (SYK) Summary page.
